Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARO-C3 in Healthy Volunteers and Patients With Complement-Mediated Renal Disease
NCT05083364Phase 2Completed
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Feb 2022
- Primary completion
- Sep 2025
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 7
01
Overview
A Phase 2 trial of ARO-C3 in Complement 3 glomerulopathy (C3G), IgA nephropathy (IgAN), sponsored by Arrowhead Pharmaceuticals. Started Feb 2022; status: completed.
02
Drugs
ARO-C3
03
Conditions
Complement 3 glomerulopathy (C3G)IgA nephropathy (IgAN)
Beyond the preview
Go deeper on NCT05083364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05083364.